Natasha E. Weiser

Nov 6, 2024 | nature.com | Oriol Pich |Kerstin Thol |Jens Luebeck |Natasha E. Weiser |Wei-Ting Lu |Brooke E. Howitt | +11 more

AbstractExtrachromosomal DNA (ecDNA) is a major contributor to treatment resistance and poor outcome for patients with cancer1,2. Here we examine the diversity of ecDNA elements across cancer, revealing the associated tissue, genetic and mutational contexts. By analysing data from 14,778 patients with 39 tumour types from the 100,000 Genomes Project, we demonstrate that 17.1% of tumour samples contain ecDNA.